Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 3,500 Shares of Company Stock

October 21, 2026 by InsiderTrades.com

Key Points

EVP Fady Malik sold 3,500 Cytokinetics shares for approximately $224,000 at an average price of $64.01, reducing his holdings by 2.22% to 153,902 shares. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan.
Cytokinetics’ shares opened at $63.95, while the company reported quarterly revenue of $28.62 million and an adjusted loss of $1.50 per share, beating analysts’ estimates but reflecting a 57.1% year-over-year revenue decline.
Analyst sentiment remains broadly positive, with 19 Buy ratings and a consensus “Moderate Buy” rating and $105.44 price target. Growth expectations are supported by MYQORZO’s Health Canada approval and expanding commercial prospects, though some analysts have lowered targets and the company continues to report losses.

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Malik sold 3,500 shares of the business's stock in a transaction on Tuesday, October 20th. The shares were sold at an average price of $64.01, for a total transaction of $224,035.00. Following the completion of the sale, the executive vice president owned 153,902 shares in the company, valued at $9,851,267.02. This represents a 2.22% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analysts Think There's Still Time to Get in on Edgewise, Up 332%

Fady Ibraham Malik also recently made the following trade(s):

On Tuesday, October 6th, Fady Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $61.38, for a total transaction of $214,830.00.
On Tuesday, September 22nd, Fady Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $68.29, for a total transaction of $239,015.00.
On Tuesday, September 8th, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $75.46, for a total transaction of $264,110.00.
On Tuesday, August 18th, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $75.82, for a total transaction of $265,370.00.

Cytokinetics Stock Up 2.1%

NASDAQ:CYTK opened at $63.95 on Wednesday. The firm has a market cap of $7.96 billion, a PE ratio of -8.86 and a beta of 0.41. Cytokinetics, Incorporated has a 12 month low of $54.30 and a 12 month high of $88.31. The company's 50-day moving average price is $69.63 and its two-hundred day moving average price is $73.23.

Want Diversified Upside in Biotechnology? Check out LABU

Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, topping the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million for the quarter, compared to the consensus estimate of $17.59 million. Cytokinetics's quarterly revenue was down 57.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.12) earnings per share. On average, research analysts expect that Cytokinetics, Incorporated will post -5.98 EPS for the current fiscal year.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

Positive Sentiment: Health Canada approved MYQORZO (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy (NYHA class II-III). The approval expands Cytokinetics’ international commercial opportunity and reinforces confidence in the drug’s regulatory and clinical profile. Health Canada approval announcement
Positive Sentiment: Coverage highlighted growing MYQORZO prescriptions, international launches and encouraging clinical data, suggesting the product could become an increasingly important growth driver for Cytokinetics. MYQORZO growth analysis
Positive Sentiment: HC Wainwright reaffirmed a Buy rating with a $140 price target, implying substantial upside from recent trading levels and providing a bullish counterpoint to more cautious views. HC Wainwright rating report
Neutral Sentiment: Cytokinetics granted options covering 60,465 shares and 40,084 restricted stock units to 29 recently hired employees as inducements. The grants support recruitment but may create modest future share dilution. Inducement grants announcement
Negative Sentiment: BofA Securities lowered its price target to $81 from $85 while maintaining a Neutral rating, signaling less near-term conviction despite the target remaining above the recent share price. BofA price-target update
Negative Sentiment: Wall Street Zen downgraded CYTK to Sell, adding to investor concerns about valuation, execution and the company’s continuing losses. Wall Street Zen rating downgrade
Negative Sentiment: Executive Vice President Fady Malik sold 3,500 shares worth approximately $224,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan, reducing its signaling value, but still represents a modest insider-selling overhang. SEC insider transaction filing

Analyst Upgrades and Downgrades

CYTK has been the topic of a number of research analyst reports. Citigroup restated a "market outperform" rating on shares of Cytokinetics in a research report on Friday, August 7th. JPMorgan Chase & Co. lifted their price objective on Cytokinetics from $97.00 to $103.00 and gave the company an "overweight" rating in a research report on Thursday, August 13th. Mizuho lifted their price objective on Cytokinetics from $100.00 to $118.00 and gave the company an "outperform" rating in a research report on Wednesday, June 24th. Needham & Company LLC boosted their price objective on Cytokinetics from $102.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Finally, Truist Financial increased their target price on Cytokinetics from $106.00 to $112.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $105.44.

View Our Latest Research Report on Cytokinetics

Institutional Investors Weigh In On Cytokinetics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CYTK. Handelsbanken Fonder AB raised its stake in shares of Cytokinetics by 63.8% in the second quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company's stock worth $34,502,000 after acquiring an additional 157,700 shares during the last quarter. Great Lakes Advisors LLC bought a new stake in shares of Cytokinetics during the second quarter valued at approximately $1,960,000. Siren L.L.C. bought a new stake in shares of Cytokinetics during the first quarter valued at approximately $40,466,000. Seven Fleet Capital Management LP grew its stake in shares of Cytokinetics by 93.0% during the second quarter. Seven Fleet Capital Management LP now owns 118,240 shares of the biopharmaceutical company's stock valued at $10,073,000 after purchasing an additional 56,971 shares during the last quarter. Finally, California State Teachers Retirement System increased its holdings in shares of Cytokinetics by 27.3% in the first quarter. California State Teachers Retirement System now owns 136,599 shares of the biopharmaceutical company's stock valued at $9,003,000 after purchasing an additional 29,275 shares in the last quarter.

Cytokinetics Company Profile

(Get Free Report)

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.